ABCDEFGHIJKLMNOPQRSTUVWXYZ
1
Model F: Economic benefit associated with the averted productivity loss due to HIV, TB, HTN, and DM mortality
2
Economic benefits model covering the benefits between 2025 and 2044
3
4
5
Summary of the differential benefits (existing - new program)
(Constant 2023 USD)
6
Overall benefit over 20 years $ 7,246,257,423,201 1,834,997,550,049Differential program cost
7
Benefit of HIV deaths averted over 20 years $ 65,292,657,791 $ 0.04 ROI
8
Benefit of Tuberculosis deaths averted over 20 years $ 57,069,601,854 $ 0.03 ROI
9
Benefit of Hypertension deaths averted over 20 years $ 5,323,016,929,022 $ 2.90 ROI
10
Benefit of Diabetes deaths averted over 20 years $ 1,800,878,234,534 $ 0.98 ROI
11
Average benefit per death over 20 years $ 67,641
12
Average benefit per person (whole population) over 20 years
 $ 84
13
14
Number of deaths averted over 20 years 107,128,540 deaths averted86079287672people total in population
15
HIV deaths averted over 20 years 1,189,526 deaths averted 1.38
deaths averted per 100,000
16
Tuberculosis deaths averted over 20 years 806,077 deaths averted 0.94
deaths averted per 100,000
17
Hypertension deaths averted over 20 years 78,555,958 deaths averted 91.26
deaths averted per 100,000
18
Diabetes deaths averted over 20 years 26,576,980 deaths averted 30.88
deaths averted per 100,000
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100